IM Cannabis Corp (IMCC) – Company Press Releases
-
IMC to transfer its Oranim Pharmacy shares back to the seller
-
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
Avant Brands Bolsters International Growth in German Cannabis Market Through Partnership with IMC
-
IMC applauds the April 1st implementation of the new Israeli cannabis regulation, facilitating access for many new patients
-
IM Cannabis Reports 2023 Financial Results
-
IMC Expects Accelerated Growth in Germany from the Country's Groundbreaking Cannabis Legalization
-
IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 28 at 9:00am ET
-
IMC Reschedules the Final Payment of the Oranim Pharmacy Acquisition
-
IMC Announces the Conclusion of the Planning and Construction Legal Proceedings
-
New Israeli cannabis regulation, facilitating access for many new patients, scheduled for December 29, 2023, has been postponed by three months; Israeli Ministry of Health published a new report showi
-
IM Cannabis Announces Receipt of Court Action
-
IM Cannabis Reports Third Quarter 2023 Financial Results
-
IM Cannabis to Report Third Quarter 2023 Financial Results on Monday, November 13 at 9:00am ET
-
IM Cannabis Releases a Message from the CEO about the Israel-Hamas War and announces securing C$1,390,000 in Short-Term Debt
-
IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer
-
IM Cannabis Announces CFO Departure
-
IM Cannabis Reports Second Quarter 2023 Financial Results
-
IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patients
-
IM Cannabis to Report Second Quarter 2023 Financial Results on Monday, August 14 at 9:00am ET
-
IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
-
IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement
-
IM Cannabis Reports First Quarter 2023 Financial Results; Gross Profit Increased 46% Year-over-Year
-
IM Cannabis Completes Debt Settlement with L5 Capital
-
IM Cannabis to Report First Quarter 2023 Financial Results on Monday, May 15 at 9:00am ET
-
IM Cannabis Announces Units for Debt Settlement
-
IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
-
IM Cannabis Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Revenues in 2022 Increased 60% Year-over-Year
-
IM Cannabis to Report Fourth Quarter & Full Year 2022 Financial Results on Wednesday, March 29 at 9:00am ET
-
IM Cannabis Announces Additional Restructuring Initiatives Designed to Drive Sustainable Profitability and Reduce Costs
-
IM Cannabis Provides an Update on Panaxia Transaction
-
Xinteza Introduces True Water-Soluble Cannabinoids Biosynthesis to Revolutionize Beverages, Cosmetics, and Pharma
-
IM Cannabis Common Shares Commence Trading on Consolidated Basis After 1 for 10 Reverse Stock Split
-
IM Cannabis Reports Third Quarter 2022 Financial Results; Revenues Increased 78% YoY and 12% Sequentially
-
IM Cannabis to Focus on Israel, German and European Growth; Commences Exiting the Canadian Cannabis Market
-
IM Cannabis to Report Third Quarter 2022 Financial Results on Monday, November 14 at 9:00am ET
-
IM Cannabis's Legacy Strain 'Roma' Voted Israel's Favourite Strain of the Month for August 2022
-
Avant Brands and IM Cannabis Announce the Launch of BLK MKT in Israel
-
Avant Brands and IM Cannabis Announce the Launch of BLK MKT in Israel
-
IM Cannabis Closes Second Tranche of Non-Brokered Private Placement of Common Shares
-
SNDL and IM Cannabis Complete SNDL's First International Export of Premium Dried Flower from Canada to Israel
-
SNDL and IM Cannabis Complete SNDL's First International Export of Premium Dried Flower from Canada to Israel
-
IM Cannabis Welcomes Two New Members to its Board of Directors
-
Xinteza Introduces Novel Key Enzyme to Solve Major Bottlenecks in Cannabinoid Biosynthesis
-
RAFAEL GABAY ACQUIRES COMMON SHARES OF IM CANNABIS CORP.
-
IM Cannabis Reports Record Second Quarter 2022 Financial Results; Revenues Increase 114% YoY to $23.8 Million
-
Xinteza Unveils Disruptive Non-Cannabaceae Source for Cannabinoid Biosynthesis in Breakthrough Research Led by Prof. Asaph Aharoni at the Weizmann Institute of Science
-
IM Cannabis to Report Second Quarter 2022 Financial Results on Monday, August 15 at 9:00am ET
-
IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
-
The Flowr Corporation Announces Fourth Quarter and Full Year 2021 Results
Back to IMCC Stock Lookup
